NASDAQ$WGS
GeneDx Holdings Corp · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
GeneDx Holdings reported Q1 2025 revenue of $87.1M, a net loss of $6.5M, diluted EPS of $-0.12.
For Q1 2025, GeneDx Holdings reported Revenue was $87.1M, net loss was $6.5M, diluted EPS was $-0.12. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $87.1M for Q1 2025.
- Net loss $6.5M.
- Diluted EPS $-0.12.
Headline financials
Revenue & EPS history
GeneDx Holdings Corp · Revenue · Quarterly
$87.1M
Forward guidance
Outlook emphasizes milestones, liquidity runway, and cost discipline.
Tailwinds
- Pipeline progress and partnership economics.
- Cash supports near-term operating plans.
Headwinds
- Operating losses until commercial scale.
- Financing and competition affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q1 2025
-0.2%
Avg return
Earnings day
-7.5%
Avg return
5 days after
-10.6%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+49.9%
Q3 2024
Best reaction
-42.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -37.6% | -18.8% | |
| Q4 2025 | +6.1% | -2.9% | -18.4% | |
| Q3 2025 | +5.2% | +4.8% | +26.7% | |
| Q1 2025 | -42.8% | -43.4% | -39.1% | |
| Q3 2024 | +49.9% | +38.7% | +41.7% | |
| Q2 2024 | -10.6% | -10.7% | -3.6% | |
| Q1 2024 | -0.7% | +77.4% | +90.9% | |
| Q3 2023 | -1.1% | -20.7% | -2.2% | |
| Q2 2023 | -0.6% | -21.2% | -34.1% | |
| Q1 2023 | -5.6% | -22.2% | -24.3% | |
| Q3 2022 | -12.2% | -39.0% | -70.8% | |
| Q2 2022 | -1.2% | -51.0% | -58.8% | |
| Q1 2022 | +10.3% | +32.1% | +1.9% | |
| Q3 2021 | -2.5% | -9.2% | -39.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro